| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Oral and Maxillofacial Surgery, University of Mainz, 55131 Mainz, Germany [T. E. R., L. S., E. M. W.], and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 [W. G., T. L. W.]
We have reported earlier that T cells found in the tumor microenvironment of head and neck cancer showed evidence of apoptosis as well as decreased expression of signaling molecules. In this prospective study, spontaneous apoptosis in tumor-infiltrating lymphocytes (TILs) and in paired circulating peripheral blood lymphocytes (PBLs) was evaluated in 28 patients with oral carcinoma and correlated with 
-chain expression and anti-CD3 antibody-induced proliferation of the PBL obtained from each patient. In addition, expression of CD3, CD4, and CD8 molecules on TIL and Fas ligand (FasL) on the tumor was studied by immunohistochemistry. Soluble FasL was measured in the patients’ sera. PBL obtained from 20 age-matched normal donors was used as a control. Reduced -chain expression was observed in TIL-T of 9 of 28 patients and in PBL-T of 12 of 28 patients. Low expression in autologous TIL-T and PBL-T was correlated (P < 0.0012), and it was associated with high levels of expression of FasL on the tumor (P = 0.0002 and P < 0.0013, respectively). Low expression in PBL-T was also associated with the poor ability of these cells to proliferate in response to anti-CD3 antibodies (P = 0.0012). Increased proportions of apoptotic cells were detected in PBL of 6 of 28 (21%) patients versus 13 of 28 patients (46%) in TIL. Apoptosis in autologous PBL and TIL was found to correlate (P = 0.0322) and was significantly associated with reduced -chain expression. Serum levels of soluble FasL were decreased in patients relative to normal controls but did not correlate with PBL apoptosis or FasL expression on the tumor. Decreased expression of TcR-associated chain, depressed immune function, and apoptosis of T cells were observed to occur concomitantly in TIL and circulating PBL-T of a subset of patients with oral carcinoma. These alterations correlated with high levels of FasL expression on the tumor but not with the disease stage. The results suggest that tumor exerts systemic suppressive effects on immune cells, which may be, in part, mediated via the Fas/FasL pathway.
This article has been cited by other articles:
|
|
 |
|
  C. Badoual, G. Bouchaud, N. E. H. Agueznay, E. Mortier, S. Hans, A. Gey, F. Fernani, S. Peyrard, P. L. -Puig, P. Bruneval, et al. The Soluble {alpha} Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer Cancer Res., May 15, 2008; 68(10): 3907 - 3914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Katou, H. Ohtani, Y. Watanabe, T. Nakayama, O. Yoshie, and K. Hashimoto Differing Phenotypes between Intraepithelial and Stromal Lymphocytes in Early-Stage Tongue Cancer Cancer Res., December 1, 2007; 67(23): 11195 - 11201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Strauss, C. Bergmann, W. Gooding, J. T. Johnson, and T. L. Whiteside The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., November 1, 2007; 13(21): 6301 - 6311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson, and T. L. Whiteside A Unique Subset of CD4+CD25highFoxp3+ T Cells Secreting Interleukin-10 and Transforming Growth Factor-{beta}1 Mediates Suppression in the Tumor Microenvironment Clin. Cancer Res., August 1, 2007; 13(15): 4345 - 4354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Molling, J. A.E. Langius, J. A. Langendijk, C. R. Leemans, H. J. Bontkes, H. J.J. van der Vliet, B. M. E. von Blomberg, R. J. Scheper, and A. J.M. van den Eertwegh Low Levels of Circulating Invariant Natural Killer T Cells Predict Poor Clinical Outcome in Patients With Head and Neck Squamous Cell Carcinoma J. Clin. Oncol., March 1, 2007; 25(7): 862 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jewett, C. Head, and N.A. Cacalano Emerging Mechanisms of Immunosuppression in Oral Cancers. J. Dent. Res., December 1, 2006; 85(12): 1061 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kim, M. Emi, K. Tanabe, and K. Arihiro Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression Cancer Res., June 1, 2006; 66(11): 5527 - 5536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Albers, C. Visus, T. Tsukishiro, R. L. Ferris, W. Gooding, T. L. Whiteside, and A. B. De Leo Alterations in the T-Cell Receptor Variable {beta} Gene-Restricted Profile of CD8+ T Lymphocytes in the Peripheral Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., April 15, 2006; 12(8): 2394 - 2403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, F. O. Ranelletti, F. Legge, V. Salutari, E. Martinelli, A. Fattorossi, D. Lorusso, G. Zannoni, V. Vellone, A. Paglia, et al. Celecoxib Up-Regulates the Expression of the {zeta} Chain of T Cell Receptor Complex in Tumor-Infiltrating Lymphocytes in Human Cervical Cancer. Clin. Cancer Res., April 1, 2006; 12(7): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Ryan, F. Shanahan, J. O'Connell, and A. M. Houston Addressing the "Fas Counterattack" Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer In vivo Cancer Res., November 1, 2005; 65(21): 9817 - 9823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Abdollahi, D. W. Griggs, H. Zieher, A. Roth, K. E. Lipson, R. Saffrich, H.-J. Grone, D. E. Hallahan, R. A. Reisfeld, J. Debus, et al. Inhibition of {alpha}v{beta}3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy Clin. Cancer Res., September 1, 2005; 11(17): 6270 - 6279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M.L. van Herpen, J. A.W.M. van der Laak, I. J. M. de Vries, J. H. van Krieken, P. C. de Wilde, M. G.J. Balvers, G. J. Adema, and P. H.M. De Mulder Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor Clin. Cancer Res., March 1, 2005; 11(5): 1899 - 1909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Bohana-Kashtan and C. I. Civin Profiling Tumor Counterattack: Do Fas Ligand-Containing Microvesicles Reduce Anticancer Immunity? Clin. Cancer Res., February 1, 2005; 11(3): 968 - 970. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Kim, E. Wieckowski, D. D. Taylor, T. E. Reichert, S. Watkins, and T. L. Whiteside Fas Ligand-Positive Membranous Vesicles Isolated from Sera of Patients with Oral Cancer Induce Apoptosis of Activated T Lymphocytes Clin. Cancer Res., February 1, 2005; 11(3): 1010 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Y. Shibuya, S. Kim, K. Nguyen, J. Do, C. E. McLaren, K.-T. Li, W.-P. Chen, P. Parikh, A. Wadhwa, X. Zi, et al. Bioactive Suture: A Novel Immunotherapy for Head and Neck Cancer Clin. Cancer Res., October 15, 2004; 10(20): 7088 - 7099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Kuss, B. Hathaway, R. L. Ferris, W. Gooding, and T. L. Whiteside Decreased Absolute Counts of T Lymphocyte Subsets and Their Relation to Disease in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., June 1, 2004; 10(11): 3755 - 3762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. van Herpen, M. Looman, M. Zonneveld, N. Scharenborg, P. C. de Wilde, L. van de Locht, M. A. W. Merkx, G. J. Adema, and P. H. De Mulder Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the Locoregional Lymph Nodes Clin. Cancer Res., April 15, 2004; 10(8): 2626 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Ginos, G. P. Page, B. S. Michalowicz, K. J. Patel, S. E. Volker, S. E. Pambuccian, F. G. Ondrey, G. L. Adams, and P. M. Gaffney Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck Cancer Res., January 1, 2004; 64(1): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Taylor, C. Gercel-Taylor, K. S. Lyons, J. Stanson, and T. L. Whiteside T-Cell Apoptosis and Suppression of T-Cell Receptor/CD3-{zeta} by Fas Ligand-Containing Membrane Vesicles Shed from Ovarian Tumors Clin. Cancer Res., November 1, 2003; 9(14): 5113 - 5119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Krishnan, D. L. Farber, and G. C. Tsokos T Cell Rewiring in Differentiation and Disease J. Immunol., October 1, 2003; 171(7): 3325 - 3331. [Full Text] [PDF]
|
|
|
|
|
|
T. L. Whiteside, Y. Zhao, T. Tsukishiro, E. M. Elder, W. Gooding, and J. Baar Enzyme-linked Immunospot, Cytokine Flow Cytometry, and Tetramers in the Detection of T-Cell Responses to a Dendritic Cell-based Multipeptide Vaccine in Patients with Melanoma Clin. Cancer Res., February 1, 2003; 9(2): 641 - 649. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
